Clover Corporation at Microequities 2010 Rising Stars Microcap Conference

8/9/2019 Clover Corporation at Microequities 2010 Rising Stars Microcap Conference

1/16

Mi

01

cro

0

eq

isi

iti

g S

s C

ars

on

er nc


2/16

www.microequities.com.au

2010 RISING STARS MICROCAP CONFERENCE

Thursday 10 of June 2010 / Level 4 Room 1/ SYDNEY HILTON (488 George St, NSW 2000)

MORNING SESSION

9:00-9:50 h. SILVER CHEF (ASX SIV) Allan English (CEO)

Charles Gregory (COO)

9:50-10:30 h. KONEKT LIMITED (ASX KKT) Serhat Oguz (CEO)

10:30-11:00 h MORNING COFFEE BREAK

11:00-11:40 h CLOVER CORPORATION (ASX CLV) Dr. Ian Brown (CEO)

11:40-12:20 h BIGAIR LIMITED (ASX BGL) Jason Ashton (Co-CEO)

12:20-13:30 h LUNCH BUFFET

AFTERNOON SESSION13:30-14:10 h. CASH CONVERTERS INTERNATIONAL

(ASX CCV)

Ralph Groom (CFO)

14:10-14:50 h. MANACCOM CORPORATION (ASX MNL) Mike Veverka (CEO)

14:50-15:20 h AFTERNOON COFEE BREAK

15:20-16:00 h PATTIES FOODS LTD (ASX PFL) Greg Bourke (CEO)

16:00-16:40 h

.XRF SCIENTIFIC LIMITED (ASX XRF) Terry Sweet (CEO)

AGENDA


3/16

Microequities is a specialised Microcap asset manager. Established in 2005 as an independentinvestment research house devoted to Microcaps. Microequities expanded into fundsmanagement in early 2009 by launching our flagship Deep Value Microcap Fund.

Why us? Microequities' investment managers and analysts operate uniquely within the Microcapasset class. This asset class offers investors access to Australian companies with an attractivegrowth profile. However, it also necessitates a systematic and process driven research approachto investing. We are uniquely positioned within the Microcap asset class and posses research

capabilities, deep knowledge and experience within the Microcap space. Our value-growthapproach, coupled with a long term investment strategy, provides us with an investment ethosthat is particularly well suited to Microcap investing.

The Deep Value Microcap Fund: Launched in March 2009, is a high conviction, value growthFund that seeks to identify and invest in growing, profitable undervalued companies. The Funddoes not have a broad based approach to investment. It maintains concentrated holdings in whatwe consider the most compelling companies within the Microcap asset class with the mostattractive risk/reward metrics. The fund has returned 83% since inception (net of fees) comparedto 43.12% for the All Ords Index.

Carlos Gil (CIO) /[email protected]/ +61 2 9231 6169

Fortbridge Consulting is a media and investor relations firm representing publicly listedcompanies. Fortbridge works with their clients to build corporate reputation and promote value.

Fortbridge investor communications programs target a range of stakeholders, includingshareholders, institutional investors and funds, as well as the financial media, in the markets in

which their clients operate.

With access to up-to-date research and investor contact information for financial centers aroundthe world, Fortbridge is able to research and maintain meaningful sector specific investor lists fortheir clients. Using this information, Fortbridge target relevant institutional investors and funds toengage their support for their clients IPOs, institutional placements, capital raisings, SPPs oron-market trades.

Fortbridge consultants in Sydney, Perth, London Toronto and Santiago have a track-record inworking with clients to build shareholders value and to grow business; to communicate the valueof new developments and to manage significant issues that impact reputation.

Bill Kemmery (Managing Director) /[email protected]/ +61 2 9331 0655

EVENT ORGANISER

EVENT SPONSOR

2010 RISING STARS MICROCAP CONFERENCE

PROFILES
mailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]


4/16

2010RisingStars

MicrocapConference

ASXCLVPresentedby Dr.IanBrown(CEO)

SYDNEYHILTON,10ofJune2010

DISCLAIMER

The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and

therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform

themselvesaboutand observe such restr ct ons.

This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or

buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or

transfer of the securitiesreferred to in this presentationin any jurisdiction in contraventionof applicable law.

Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent

financial advisor. Certain statements made in this presentation are forwardlooking statements. These forwardlooking

statements are not historical facts but rather are based on Clover Corporations current expectations, estimates and

projections about the industry in which Clover Corporation operates, and its beliefs and assumptions. Words such as

"anticipates," "expects," "intends," "plans," "believes," "seeks, "estimates," and similar expressions are intended to

identify forwardlooking statements.

These statements are not guarantees of future performance and are subject to known and unknown risks,

uncertainties and other factors, some of which are beyond the control of Clover Corporation, are difficult to predict

and could cause actual results to differ materially from those expressed or forecasted in the forwardlooking

statements. Clover Corporation cautions shareholders and prospective shareholders not to place undue reliance on

these forwardlooking statements, which reflect the view of Clover Corporation only as of the date of this

presentation. The forwardlooking statements made in this presentation relate only to events as of the date on which

the statements are made. Clover Corporation will not undertake any obligation to release publicly any revisions or

updates to these forwardlooking statements to reflect events, circumstances or unanticipated events occurring after

the date of this presentationexcept as required by law or by any appropriate regulatory authority.


5/16

INTRODUCTION

C overCorporationLimite provi esnutritiona an unctiona

ingredientsforuseininfantformula,foodsandspecialty

applicationsusingproprietarytechnology.

FutureFood

Ingredients(50%)(100%)

COMPANYOVERVIEW

Missionistoidentify,developandcommercialisespecialty

functionalandnutritionalingredients.

Consistentlyprofitable,

strong

cash

position

&

zero

debt.

Competitivepositioninthegrowingnutraceuticalmarket.

Strongtechnical,manufacturingandsalesorganisation.

ocusonpropr e ary pa en e ec no ogy.

Focusonbioactivedeliveryincludingmicroencapsulation.


6/16

million ($)

HISTORICALFINANCIAL

PERFOMANCE

Amountof

'

HALFYEARENDED

31DECEMBER2009

$'000

Revenuefromordinaryactivities Up 58.3% 6,173 to 16,760

Profitbefore

tax

(excluding FFI)Up 39.1% 882 to 3,140

Profitbeforetax

(includingFFI)

Up 30.8% 635 to 2,699

Profitfromordinaryactivities

aftertax

Up 18.8% 303 to 1,912

Netprofitfortheperiod Up 18.8% 303 to 1,912


7/16

AssociatesandJointVentureentities

HALFYEARENDED

31DECEMBER

2009

Interestin

Associates

31Dec2009

$'000

31Dec2008

$'000

FutureFoodIngredientsPtyLimited 50%

shareofnetassets 2,730 3,408

share of net loss 441 195

Detailsofshareandresultsinassociates

loan

from

Clover

Corporation

Limited 1,618 1,618

Revenueof80%to$16.4million

80%INCREASEINSALES

REVENUEDURING1HFY10

million($)


8/16

Profitaftertaxup18.8%to$1.9million

NPATUP+18.8%

FOR1H

FY10

million($)


9/16

Overview

NUMEGAINGREDIENTS

PTYLTD

Australianproducer&internationalsupplier ofmicroencapsulatedpowders.

Encapsulationprocessispatentedinmanycountries.

Currentspecialtiesincludeomega3&omega6oils(marine&algalsources).

Processprotectsoilfromoxidation(fishytaste&smell).

RefineandpreparehighqualitytunaoilinAltona,Victoria.

Extensiveexpertiseinapplicationtechnology.

Actively

involved

in

clinical

research. Dedicated&professionalstaff.

OMEGA3MARKET

ISGROWING

GlobalOmega3ingredientmarketestimated

at+US$700million

ForecastedCAGR

NorthAmerica:14%

Europe:8%

USmarket heavyemphasisonflaxhowever

thereisagrowingawareness&trendtoward

marine&algalomega3oils


10/16

NUMEGASALES&

DISTRIBUTIONNETWORK

InassociationwithGTCNutrition

SALESOFFICE MANUFACTURINGSITE AGENTS

GTC NutritionDirect Sales Team

EuropeUnited Kingdom GTC Nutrition

Benelux re ion Lithos

GTCNUTRITIONMARKET

COVERAGEINTHE

AMERICASANDEUROPE

Canada, U.S.

CP IngredientesMexico

Corn Products

Germany, Austria, Switzerland,

Eastern Europe Chemopharma

Italy Azelis, Alesco

Ireland Norman Lauder

Seeking for:

France, Spain, Scandinavia

rgent na

BoliviaBrazil

ChileColombia

EcuadorParaguay

PeruVenezuela

Uruguay

The mission of GTC Nutrition is to be a premier provider of science-based,healthy ingredient solutions with unique commercial applications that improve

the quality of life for humans and animals and, in doing so, generateappropriate returns for our stake-owners.


11/16

Heart Bone Immune Glycemic Digestive CognitiveHealth Health Health Health Health Health

GTC:OMEGA3DHA

STRATEGICFIT

Infant&ChildrensFormula

FOCUSON

INFANTFORMULA

Stronglygrowingmarketforinfant&childrensformulation.

FastestgrowingregionisAsia(CAGR+10%) butevendevelopedmarketssuchasthe

USAandEuropearepositive.

Demonstrated&

acknowledged

health

benefits.

NuMegasPosition

r p orm unaan ora ga pow ers ave emons ra e unc ona ene s.

Highqualitymanufacturingfacilities

NuMegasuppliesanumberofthelargestinfantformulaproducers,includingMead

JohnsonNutritionals.

Activeprogramtodevelopnewingredients.


12/16

NUMEGA

SALES

IN

FY09

Australia/New Zealand 25%

Asia 59%

Europe 9%

USA 7%

Oil 15%

eograp c

Products

pp ca ons

Powder 80%

Soy 5%

DIVERSIFYING

ENCAPSULATEDPRODUCTS

IntroducingnewproductsinFY09

Revenue

from

Existing

Products 65%RevenuefromNewProducts

(releasedinthepast3years)35%


13/16

Increasedsalesofingredientsforinfantformulaandfoods.

OVERVIEW1H

FY10

Increasedsalesareduetobothnewcustomers,particularlyinAsia,andthe

successofexistingfoods.

Increaseinreceivablesandinventories,associatedwithexpandedsalesandthe

relatedtradingterms.

Commercialintroductionofnewencapsulatedproducts.

SalesofvalueaddedNuSoyaingredients,throughthedistributorNuMega

IngredientsPtyLtd,increasedby29%duringthefirsthalfofthefinancialyear

comparedto

the

same

period

last

year.

Competitivemarketwithpressureonmargins.

CHALLENGESAND

OPPORTUNITIESFORFY10

Increasedinput&rawmaterialcosts.

Investtobuildforthefuture.

ExpandsalesthroughGTCNutrition.

CommercialisetheoutcomesoftheR&Dprogram.

Expandaccesstobioactiverawmaterialsincludingomega3oils.

Protect&utilizeintellectualproperty.

en ycomp men ary us nessoppor un es.


14/16

FutureFoodIngredients

FUTUREFOOD

INGREDIENTS

JointVentureofCloverCorporation&Austgrains (50:50)

ManufacturingfacilitylocatedinMoree,NSW

ManagedbyFFIBoard.

NuSoya blandflavourtechnologyexclusivelylicensedby

FFI

Sales

EatRite FFI/Austgrains

NuSoya NuMegaIngredients

Productrangeincludingsplits,flakes,gritsandfloursinconventionalororganic&plainortoasted


15/16

Equityaccountedlosstothecompanyof$441,000(2008:$195,000)forthe

FFI/1H

FY10

RESULTS

periodunderreview.

EventhoughsalesrevenueforFFIincreasedtheproductmix,operationaland

inventoryissuescontributedsignificantlytotheloss.

Understrategicandoperationalreview

ManagementofFFIhasrevertedfromAustgrainstotheFFIBoard.

FFIBoardhasinitiatedanintensivebusinessdevelopmentprogramandafinancialreviewofFFItorefocusthecompanyandreducethelossesinthe

secondhalf

of

the

year

Outlook

2010

CloverCorporation


16/16

ContinuestrongsalesfromOmega3ingredients.

OUTLOOK2010

RestructureFFI

Capitaliseonexpandedsales&distributionnetwork.

Expandthecustomerbase.

Increaseopportunitiesinfoodapplications.

Selectivelyrecruitforgrowth.

Continuedevelopment

of

encapsulation

technology.

Identifynewtechnical&commercialopportunities.

THANKYOU

Questions?

Clover Corporation at Microequities 2010 Rising Stars Microcap Conference

Documents

Transcript of Clover Corporation at Microequities 2010 Rising Stars Microcap Conference